An Essential First Step in Market Access for Medicines

What is UK PharmaScan?

UK PharmaScan is a database of information on new medicines, indications and formulations in the pharmaceutical pipeline. It is the primary source of information used by all of the UK's national horizon scanning organisations and NHS England to enable early engagement in planning and preparing the NHS for the introduction of new medicines and to support faster NHS adoption.

Why is UK PharmaScan important for your business?

UK PharmaScan is an essential first step in securing market access for new medicines. Early engagement and NHS planning have been shown to improve the speed of medicines uptake. Underpinned by the information available through UK PharmaScan, this planning relies on regular and comprehensive data entry by product developers.

Providing timely and relevant data enables the UK's national horizon scanning organisations to inform key stakeholders in the NHS in England, Scotland and Wales, so they can plan for the introduction of new medicines, indications and formulations. This is essential to ensure the NHS can optimise the delivery of new medicines to patients.

The importance of timely and accurate information is reinforced in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access which restates the shared ambition that the NHS must have complete and accurate information about products coming through the pipeline (paragraphs 3.4-3.9). Pharmaceutical companies are required to provide timely, accurate and comprehensive information on products and indications in development.

UK PharmaScan data

- Information on medicine/indication/formulation
- Clinical trial information
- Regulatory information
- Cost and budget impact data

NHS England and Horizon Scanning Organisations

- National pathway and system planning, identification of transformative medicines for the Accelerated Access Collaborative
- Topic selection and scheduling for HTA by NICE, SMC, AWMSG
- Local planning: formulary development, service design and budgeting
- Informing national planning and prioritising engagements
The Role of **UK PharmaScan** in Optimising Market Access for Medicines

**Market access routes in England**

1. **New Molecular Entity, New Indication or Formulation**

**UK PharmaScan - an Essential First Step to Early Market Access for Medicines**

**Working Across The System**

- **Horizon Scanning**
  - Horizon Scanning report
  - Prescribing Outlook

- **NICE (National Institute for Health and Care Excellence)**
- **NIHR (National Institute for Health Research)**
- **Specialist Pharmacy Service**
- **NHS England**

- **Clinical Commissioning Groups (CCGs)**
- **Provider Trusts**

**Decision Maker**

- **NCE Centre for Health Technology Evaluation**

**Access Route**

- **Technology Appraisal** (Single, Multiple, Fast-track Appraisal)
- **Highly Specialised Technologies Evaluation**

**Output**

- **Guidance**
- **Formulary Decision and Publication**

**Funding**

- **Mandated Funding**
  - Cancer Drugs Fund
- **CCG Funding**

**National pathway and system planning**

- **Identification of transformative medicines**

**Market access routes in Scotland and Wales**

- **New Molecular Entity, New Indication or Formulation**

**UK PharmaScan - an Essential First Step to Early Market Access for Medicines**

**Scotland**

- **Healthcare Improvement Scotland Scottish Medicines Consortium**

**Wales**

- **All Wales Medicines Strategy Group**

**Decision Maker**

- **Scottish Medicines Consortium**

**Access Route**

- **Technology Appraisal** (Standard, End-of-life, Ultra-orphan)

**Output**

- **Guidance**
- **Horizon Scanning Report 'Forward Look'**

**Funding**

- **Mandated Funding**
- **Health Boards**
- **NICE Guidance**
What do NHS England and the horizon scanning organisations say?

The NIHR Innovation Observatory (NIHRIO) uses UK PharmaScan to ensure that information on new and repurposed medicines, that are actively being monitored, is up-to-date and reliable. This allows us to produce timely and accurate horizon scanning intelligence to notify NICE and other national organisations to support decision-making and planning for the future.

UK PharmaScan is a key source of information in the production of our annual horizon scanning report, Forward Look, which informs financial planning for emerging new medicines in all Scotland’s Health Boards and National Specialist Services. It also highlights new medicines, indications and formulations for future health technology appraisal in Scotland.

Horizon scanning is a vital tool to understand the future healthcare environment and UK PharmaScan is a key source of data to help NHS England plan for future healthcare interventions. UK PharmaScan is therefore an essential first step for manufacturers in their market access preparations.

NICE uses UK PharmaScan to track licensing information as part of the topic selection, scoping and assessment stages of the Technology Appraisal and Highly Specialised Technologies programmes. This ensures we are able to produce national guidance that enables funding and patient access to medicines within a few months of marketing authorisation.

UK PharmaScan is our go-to resource for information on UK pipeline products. It is able to provide data for NHS planning purposes that no other resource can.

Information in UK PharmaScan is key in helping us support health boards and trusts across NHS Wales plan for new medicines, indications and formulations, in particular those with significant budgetary and/or service delivery implications.

How can I find out more about UK PharmaScan? Go online at www.ukpharmascan.org.uk

Resources
A comprehensive range of information, guidance, training and examples is available online to support you: www.ukpharmascan.org.uk/static/about

Register
To register go to: www.ukpharmascan.org.uk/static/howtoregister
Already registered? Login at: www.ukpharmascan.org.uk/login

Help
The NICE helpdesk is available from 9am to 5pm Monday to Friday to assist with any access or technical issues: contactus@ukpharmascan.org.uk

Confidential and secure
Data entered on your medicines are ONLY accessible to you, NHS England and the horizon scanning organisations above. All organisations are covered by specific confidentiality provisions in user agreements and robust security safeguards are in place.